Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]

Affiliations

• ¹ Institute Gustave Roussy, Villejuif, France. Electronic address: escudier@gustaveroussy.fr.
• ² MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
• ³ Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
• ⁴ Roswell Park Cancer Institute, Buffalo, NY, USA.
• ⁵ Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
• ⁶ Stanford Cancer Institute, Stanford, CA, USA.
• ⁷ University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
• ⁸ Vanderbilt University Medical Center, Nashville, TN, USA.
• ⁹ Fondazione Istituto Nazionale Tumori, Milan, Italy.
• ¹⁰ Fox Chase Cancer Center, Philadelphia, PA, USA.
• ¹¹ Hospital Universitario 12 De Octubre, Madrid, Spain.
• ¹² Westmead Hospital, Westmead, NSW, Australia.
• ¹³ Aarhus University Hospital, Aarhus, Denmark.
• ¹⁴ Comprehensive Cancer Center, Helsinki University Central Hospital Cancer Center, Helsinki, Finland.
• ¹⁵ South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK.
• ¹⁶ University Hospital Essen of University of Duisburg-Essen, Essen, Germany.
• ¹⁷ Chiba Cancer Center, Chiba, Japan.
• ¹⁸ Bristol-Myers Squibb, Princeton, NJ, USA.
• ¹⁹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.